DSciLab Co., Ltd, a China-based mRNA pharmaceutical company nurtured by Fosun Health Capital, has announced the completion of an angel financing round worth RMB 100 million. The round was led by Fosun Health Capital, with participation from Shanghai Creation Investment. The funds will be directed towards the advancement of core pipelines such as DSL101 and DSL201, the development of an LNP delivery system, expansion of the pipeline layout, and enhancements in research and development (R&D) capabilities and daily operations.
Established in June 2022, DSciLab specializes in the development of in vivo targeting and isolation technology for lipid nanomedicine and a highly efficient mRNA delivery system that is designed to have minimal immunogenicity. The company’s pipelines, DSL101 and DSL201, are being prepared for clinical filings. DSciLab set up an R&D center in Shanghai last year, marking a significant step in its commitment to innovation in the mRNA therapeutics space.- Flcube.com
